In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex. (11th November 2013)

• Record Type: Journal Article
• Authors: Lavollay, M.; Dubée, V.; Heym, B.; Herrmann, J.‐L.; Gaillard, J.‐L.; Gutmann, L.; Arthur, M.; Mainardi, J.‐L.; Allerberger, F.
• Is Part Of: Clinical microbiology and infection. Volume 20:Number 5(2014:May)
• Page Start: O297
• Page End: O300
• Publication Date: 2013-11-11
• Subjects: Medical microbiology -- Periodicals; Diagnostic microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.01
• DOI: 10.1111/1469-0691.12405
• Languages: English
• ISSNs: 1198-743X

Abstract

<abstract abstract-type="main" id="clm12405-abs-0001"> <title>Abstract</title> <p>The <italic>in vitro</italic> activity of cefoxitin and imipenem was compared for 43 strains of the <italic>Mycobacterium abscessus</italic> complex, mostly isolated from cystic fibrosis patients. The MICs of imipenem were lower than those of cefoxitin, although the number of imipenem‐resistant strains was higher according to the CLSI breakpoints. Strain comparisons indicated that the MICs of cefoxitin were significantly higher for <italic>Mycobacterium bolletii</italic> than for <italic>M</italic>. <italic>abscessus</italic>. The MICs of both β‐lactams were higher for the rough morphotype than for the smooth morphotype. The clinical impact of the <italic>in vitro</italic> difference between the activity of imipenem and that of cefoxitin remains to be determined.</p> </abstract>